Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Orexo Ab

Kirsten Arndt

Dirk Stenkamp

Henri Doods

Klaus Rudolf

Stephan Georg Mueller

Philipp Lustenberger

Gerhard Schaenzle

Marco Santagostino

Fabio Paleari

Alexander Dreyer

Roland Pfau

Raimund Kuelzer

Klaus Klinder

Norbert Hauel

Marcus Schindler

Eckhart Bauer

Juergen Mack

Henning Priepke

Gerald Juergen Roth

Kai Gerlach

Rudolf Hurnaus

Thorsten Lehmann-Lintz

Martin Lenter

Thierry Bouyssou

Benjamin Pelcman

Ralf Lotz

Ralf R H Lotz

Edgars Suna

Robert Roenn

Dimitrijs Lubriks

Heike-Andrea Wieland

Philip Lustenberger

Ralf R Lotz

Gerald Jurgen Roth

Rudlof Klaus

Stephan-Georg Müller

Ralf Richard Hermann Lotz

There are provided compounds of formula (I), wherein R, R, R, Q, Q, Q, Q, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer. 

1H-benzimidazole-5-carboxamides as anti-inflammatory agents

The present invention relates to compounds of general formula I in which A, L, M, Q, Q, Q, R, R, R, R, R, W, X, Y, Z, Z, Zare defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof. The compounds are of potential utility in the treatment and/or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and/or prevention of pain. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.

Compounds

1H-benz imidazole-5-carboxamides as anti-inflammatory agents

3H-imidazo [4, 5-B] pyridine-6-carboxamides as anti-inflammatory agents

3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents

The present invention relates to the CGRP antagonists of general formula wherein A, X, D, E, G, M, Q and Rto Rare defined as in claimthe tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

The present invention relates to the CGRP-antagonists of general formula I wherein R, R, Rand Rare defined as in claim, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I wherein one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Selected CGRP-antagonists, processes for preparing them and their use as pharmaceutical compositions

The present invention relates to the CGRP antagonists of general formula I wherein R, R, Rand Rare as defined in claim, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I wherein one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions

The invention relates to a method for treating irritable bowel syndrome through the use of effective amounts of a compound acting as CGRP antagonist.

CGRP antagonists

CGRP antagonists of the formula of which the following are exemplary:

The present invention relates to the CGRP antagonists of general formula wherein A, X, D, E, G, M, Q and Rto Rare defined as in claim,the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

The present invention relates to the CGRP-antagonists of general formula I wherein R, R, R, Rand X are defined as in claim, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, mixtures and salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I in which one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

The present invention relates to the CGRP antagonists of general formula wherein A, X, Q and Rto Rare defined as in claim, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, mixtures and salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

The present invention relates to the CGRP antagonists of general formula wherein A, X, D, E, G, M, Q and Rto Rare defined as in claim 1,

The present invention relates to the CGRP antagonists of general formula I wherein R, R, Rand Rare defined as in claim, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I wherein one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Growing community of inventors

Biberach, Germany

Kirsten Arndt